Front page text
ImmunID: personalizing cancer immunotherapy based on the patient’s immune status
ImmunID adds precision to the immuno-oncology revolution by personalizing immunotherapy. We provide doctors with clinically meaningful data on the highly complex immune system to select the right therapy for individual patients and to monitor their response. ImmunID’s flagship product ImmunTraCkeR® evaluates the patient’s immune status based on the T lymphocyte diversity, from a simple liquid biopsy. We are establishing ImmunTraCkeR® as the general immune companion diagnostic test for immune checkpoint inhibitors and other immunotherapies. In addition, ImmunID collaborates with pharma and biotech companies to optimize the development of their next-generation immunotherapies.